Fresh analysis indicates that individuals who come off new weight-loss injections like Wegovy and Mounjaro may regain reduced body mass far faster than those who halt conventional lifestyle programs.
Research printed in a leading health publication points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Individuals using such drugs need to be informed of the danger of rapid rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
This pace of regain suggests a reversion to starting weight in about 18 months.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
The team emphasize that individuals who lose weight through dieting typically see a more gradual weight regain—around 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Experts suggest the way of the injections explains the amplified weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating far more likely."
A Lifelong Issue?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the treatment might need to be long-term.
This perspective is echoed by pharmaceutical companies, who state that the results "underscore the persistent nature of excess weight," comparing it to managing conditions like diabetes.
User Experiences
Users who have stopped the medication describe a intense resurgence of appetite.
"It felt as if something that goes on and I was suddenly extremely hungry," said an individual.
The struggle is exacerbated if users have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among females than males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic fix and long-term success relies on ongoing behavioural support.
